Day: October 14, 2021

Authors Wang, RH; Li, YL; He, HJ; Xiao, YC; Chen, FE in WILEY-V C H VERLAG GMBH published article about ENANTIOSELECTIVE ADDITION; TERTIARY ALCOHOLS; PYRAZOLONE DERIVATIVES; ORGANOZINC REAGENTS; ALKYLZINC REAGENTS; ALPHA-KETOESTERS; KETONES; DIETHYLZINC; HYDROXYLATION; DIMETHYLZINC in [Wang, Rong-Hui; Li, Ya-Ling; He, Hong-Jiao; Xiao, You-Cai; Chen, Fen-Er] Sichuan Univ, Sichuan Res Ctr Drug Precis Ind Technol, West China Sch Pharm, Chengdu 610041, Peoples R China; [Chen, Fen-Er] Fudan Univ, Engn Ctr Catalysis & Synth Chiral Mol, Dept Chem, Shanghai 200433, Peoples R China; [Chen, Fen-Er] Shanghai Engn Ctr Ind Asymmetr Catalysis Chiral D, Shanghai 200433, Peoples R China in 2021, Cited 67. Recommanded Product: 86-92-0. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0

The catalytic enantioselective diorganozinc additions to cyclic diketones including pyrazolin-4,5-diones and isatins have been developed. In the presence of morpholine-containing chiral amino alcohol ligand, the corresponding chiral cyclic tertiary alcohols were produced in good to excellent yields (up to 97 %) and enantioselectivities (up to 95 % ee). The notable feature of this protocol includes its mild reaction conditions, Lewis acid additives free and broad functional group tolerance.

About 3-Methyl-1-p-tolyl-5-pyrazolone, If you have any questions, you can contact Wang, RH; Li, YL; He, HJ; Xiao, YC; Chen, FE or concate me.. Recommanded Product: 86-92-0

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

An article Regioselectivity Switch in Palladium-Catalyzed Allenylic Cycloadditions of Allenic Esters: [4+1] or [4+3] Cycloaddition/Cross-Coupling WOS:000462622700046 published article about ASYMMETRIC-SYNTHESIS; SPIROPYRAZOLONES; ISOXAZOLINONES; DENDRALENES; ANNULATION; GENERATION; REACTIVITY; YLIDES in [Li, Long; Luo, Pengfei; Deng, Yuhua; Shao, Zhihui] Yunnan Univ, Key Lab Med Chem Nat Resource, State Key Lab Conservat & Utilizat Bioresources Y, Minist Educ,Sch Chem Sci & Technol, Kunming 650091, Yunnan, Peoples R China in 2019, Cited 65. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0. Category: pyrazoles-derivatives

The first Pd-catalyzed asymmetric allenylic [4+1] cycloaddition was successfully developed. Alternatively, tuning the Pd catalyst switched the reactivity toward an unprecedented [4+3] cycloaddition/cross-coupling. Ligands play a vital role in controlling the reaction pathway, allowing highly selective access to different products from identical substrates. Biological evaluation of the obtained compounds led to the discovery of new antitumor targets. A possible mechanism is proposed, suggesting two interesting catalytic cycles for the cycloaddition with palladium-butadienyls. This study also demonstrated the potential and utility of allenic esters as 1,4-biselectrophiles and C-4 synthons for participating in cycloaddition reactions.

Category: pyrazoles-derivatives. About 3-Methyl-1-p-tolyl-5-pyrazolone, If you have any questions, you can contact Li, L; Luo, PF; Deng, YH; Shao, ZH or concate me.

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Name: 3,5-Dimethyl-1H-pyrazole. Tansky, M; Gu, ZP; Comito, RJ in [Tansky, Maxym; Gu, Zipeng; Comito, Robert J.] Univ Houston, Houston, TX 77004 USA published Metal-free, Mild, and Selective Synthesis of Bis(pyrazolyl)alkanes by Nucleophile-Catalyzed Condensation in 2021, Cited 41. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6.

Bis(pyrazolyl)alkanes are a prolific class of ligands for catalysis, accessible by the condensation between bis(pyrazolyl)methanones and carbonyls. In this report, we describe a nucleophile-catalyzed innovation on this condensation that avoids the transition metals, high temperatures, reagent excess, and air-sensitive reagents common among the existing protocols. Significantly, this method accommodates sterically hindered and electronically diverse pyrazoles and aldehydes, applicable for systematic ligand optimization. Furthermore, our scope includes azoles and bridging functional groups previously unreported for this reaction, promising for new heteroscorpionate catalysts. We provide the first direct evidence for an elusive reaction intermediate and characterize the most complete mechanism for this condensation.

Name: 3,5-Dimethyl-1H-pyrazole. About 3,5-Dimethyl-1H-pyrazole, If you have any questions, you can contact Tansky, M; Gu, ZP; Comito, RJ or concate me.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

I found the field of Oncology very interesting. Saw the article Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients published in 2020. Recommanded Product: 83-10-3, Reprint Addresses Buchler, T (corresponding author), Charles Univ Prague, Fac Med 1, Dept Oncol, Videnska 800, Prague 14059, Czech Republic.; Buchler, T (corresponding author), Charles Univ Prague, Thomayer Hosp, Videnska 800, Prague 14059, Czech Republic.. The CAS is 83-10-3. Through research, I have a further understanding and discovery of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid

Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.

Recommanded Product: 83-10-3. About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Novakova-Jiresova, A; Kopeckova, K; Boublikova, L; Chloupkov, R; Melichar, B; Petruzelka, L; Finek, J; Fiala, O; Grell, P; Batko, S; Linke, Z; Kiss, I; Prausov, J; Buchler, T or concate me.

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Formula: C5H8N2. In 2020.0 SEP SCI TECHNOL published article about ACTIVATED CARBON; LIQUID; EXTRACTION; EQUILIBRIUM; ADSORPTION; STABILITY; SOLVENTS; RECOVERY; SALTS; DYES in [Ozdemir, Melek Canbulat] Middle East Tech Univ, Fac Engn, Dept Environm Engn, TR-06800 Ankara, Turkey in 2020.0, Cited 54.0. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6.

The removal of methylene blue (MB) from aqueous solution has been investigated using new tunable 1-aryl-2-alkyl-3,5-dimethylpyrazolium hexafluorophosphate salts ([Ph(R)C(R?)pz][PF6], R: -Cl, -Br, -Me, -OMe, R?: -C2H5, or -C4H9) as an extractant and methylene chloride as a diluent. The influence of p-substituent and alkyl chain length on the removal efficiency of MB from aqueous solution was investigated. The obtained results show that MB was extracted from aqueous solution with high extraction efficiency up to 99.7 % in a very short time. The salt (4a) used for extraction of MB was recovered and reused for four runs.

Formula: C5H8N2. About 3,5-Dimethyl-1H-pyrazole, If you have any questions, you can contact Ozdemir, MC or concate me.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

COA of Formula: C5H8N2. In 2019.0 EUR J INORG CHEM published article about RAY CRYSTAL-STRUCTURE; STRUCTURAL-CHARACTERIZATION; AGOSTIC INTERACTIONS; BOND; REACTIVITY; LIGAND; CHEMISTRY; BEHAVIOR; DESIGN; FE in [Zhao, Qianyi; Dou, Ting; Guan, Xin-Ting; Xu, Ting; Chen, Ming-Jing; Zhang, Jie; Chen, Xuenian] Henan Normal Univ, Sch Chem & Chem Engn, Minist Educ,Collaborat Innovat Ctr Henan Prov Gre, Henan Key Lab Boron Chem & Adv Energy Mat,Key Lab, Xinxiang 453007, Henan, Peoples R China; [Chen, Xuenian] Zhengzhou Univ, Coll Chem & Mol Engn, Zhengzhou 450001, Henan, Peoples R China in 2019.0, Cited 56.0. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6.

Three kinds of Ni-II complexes, the singly hydroxo-bridged complex 2, doubly hydroxo-bridged complexes 3a and 3b, and dinuclear Ni complex 4, were readily prepared from reactions of the salt K[(BBN)Bp (R)] {(BBN)Bp (R) = (9-BBN)bis(pyrazolyl)borate} and the NiCl2(PPh3)(2) precursor via B-N bond cleavage process in dichloromethane or toluene. Complex 2 is a rare example of partial hydrolysis of the coordinated pyrazolylborate ligand, while complexes 3a and 3b demonstrate the unreported new form that complete hydrolyses of the coordinated pyrazolylborate ligand produced. Different mechanisms for the formation of complexes 2-4 are proposed.

About 3,5-Dimethyl-1H-pyrazole, If you have any questions, you can contact Zhao, QY; Dou, T; Guan, XT; Xu, T; Chen, MJ; Zhang, J; Chen, XN or concate me.. COA of Formula: C5H8N2

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

Recommanded Product: 67-51-6. Yu, Y; Yuan, Y; Liu, HL; He, M; Yang, MZ; Liu, P; Yu, BY; Dong, XC; Lei, AW in [Yu, Yi; Liu, Huilin; He, Min; Yang, Mingzhu; Liu, Pan; Yu, Banying; Dong, Xuanchi; Lei, Aiwen] Jiangxi Normal Univ, Natl Res Ctr Carbohydrate Synth, Nanchang 330022, Jiangxi, Peoples R China; [Yuan, Yong; Lei, Aiwen] Wuhan Univ, IAS, Coll Chem & Mol Sci, Wuhan 430072, Hubei, Peoples R China published Electrochemical oxidative C-H/N-H cross-coupling for C-N bond formation with hydrogen evolution in 2019.0, Cited 59.0. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6.

Under metal catalyst-free and exogenous-oxidant-free conditions, a series of C-3 aminated imidazo[1,2-a]pyridines were synthesized by electrochemical intermolecular oxidative C-H/N-H cross-coupling. Furthermore, by using a catalytic amount of ferrocene as the mediator, electrochemical intramolecular oxidative C-H/N-H cross-coupling for the synthesis of 10H-benzo[4,5] imidazo[1,2-a]indole derivatives has also been accomplished.

About 3,5-Dimethyl-1H-pyrazole, If you have any questions, you can contact Yu, Y; Yuan, Y; Liu, HL; He, M; Yang, MZ; Liu, P; Yu, BY; Dong, XC; Lei, AW or concate me.. Recommanded Product: 67-51-6

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

In 2021 AGE AGEING published article about DRUG-REACTIONS; MEDICATION USE; OLDER-PEOPLE; CARE; COMORBIDITIES in [Delgado, Joao; Jones, Lindsay; Ballard, Clive; Melzer, David] Univ Exeter, Coll Med & Hlth, Epidemiol & Publ Hlth, Exeter EX1 2LU, Devon, England; [Bradley, Marie C.] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA; [Allan, Louise M.; Clare, Linda] Univ Exeter, Coll Med & Hlth, Ctr Res Ageing & Cognit Hlth, Exeter EX1 2LU, Devon, England; [Fortinsky, Richard H.] Univ Connecticut, Sch Med, Ctr Aging, Mansfield, CT 06030 USA; [Hughes, Carmel M.] Queens Univ Belfast, Med Biol Ctr, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland in 2021, Cited 30. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3. Category: pyrazoles-derivatives

Importance: treatment of dementia in individuals with comorbidities is complex, leading to potentially inappropriate prescribing (PIP). The impact of PIP in this population is unknown. Objective: to estimate the rate of PIP and its effect on adverse health outcomes (AHO). Design: retrospective cohort. Setting: primary care electronic health records linked to hospital discharge data from England. Subjects: 11,175 individuals with dementia aged over 65 years in 2016 and 43,463 age- and sex-matched controls. Methods: Screening Tool of Older Persons’ Prescriptions V2 defined PIP. Logistic regression tested associations with comorbidities at baseline, and survival analyses risk of incident AHO, adjusted for age, gender, deprivation and 14 comorbidities. Results: the dementia group had increased risk of PIP (73% prevalence; odds ratio [OR]: 1.92; confidence interval [CI]: 83-103%; P < 0.01) after adjusting for comorbidities. Most frequent PIP criteria were related to anti-cholinergic drugs and therapeutic duplication. Risk of PIP was higher in patients also diagnosed with coronary-heart disease (odds OR: 2.17; CI: 1.91-2.46; P < 0.01), severe mental illness (OR: 2.09; CI: 1.62-2.70; P < 0.01); and depression (OR: 1.81; CI: 1.62-2.01; P < 0.01). During follow-up (1 year), PIP was associated with increased all-cause mortality (hazard ratio: 1.14; CI: 1.021.26; P < 0.02), skin ulcer and pressure sores (hazard ratio: 1.66; CI: 1.12-2.46; P< 0.01), falls (hazard ratio: 1.37; CI: 1.15-1.63; P < 0.01), anaemia (hazard ratio: 1.61; CI: 1.10-2.38; P < 0.02) and osteoporosis (hazard ratio: 1.62; CI: 1.022.57; P < 0.04). Conclusion: patients with dementia frequently receive PIPs, and those who do are more likely to experience AHO. These results highlight the need to optimise medication in dementia patients, especially those with comorbidities. About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Delgado, J; Jones, L; Bradley, MC; Allan, LM; Ballard, C; Clare, L; Fortinsky, RH; Hughes, CM; Melzer, D or concate me.. Category: pyrazoles-derivatives

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Glukhacheva, VS; Il’yasov, SG; Kazantsev, IV; Shestakova, EO; Il’yasov, DS; Eltsov, IV; Nefedov, AA; Gatilov, YV in [Glukhacheva, Vera S.; Il’yasov, Sergey G.; Kazantsev, Igor, V; Shestakova, Elena O.; Il’yasov, Dmitri S.] Russian Acad Sci IPCET SB RAS, Inst Problems Chem & Energet Technol, Siberian Branch, Biisk 659322, Russia; [Eltsov, Ilia, V; Nefedov, Andrey A.] Novosibirsk State Univ, Novosibirsk 630090, Russia; [Nefedov, Andrey A.; Gatilov, Yuri, V] Russian Acad Sci NIOCh SB RAS, Vorozhtsov Novosibirsk Inst Organ Chem, Siberian Branch, Novosibirsk 630090, Russia published New Reaction Products of Acetylacetone with Semicarbazide Derivatives in 2021.0, Cited 40.0. Recommanded Product: 67-51-6. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6.

A new approach is suggested herein for the synthesis of pyrazole derivatives by reacting 4-nitrosemicarbazide with acetylacetone. Additional studies were done on the reaction of acetylacetone with semicarbazide and its derivatives (4-aminosemicarbazide, methylsemicarbazide, and dimethylsemicarbazide). The study on the reaction with acetylacetone resulted in monocyclic 3,5-dimethyl-N-nitropyrazole-1-carboxamide, monocyclic 5-hydroxy-3,5-dimethyl-2-pyrazoline, and bicyclic bis(3,5-dimethylpyrazole-1-carbonyl)hydrazine, and conditions for the formation of acetone semicarbazone were identified. The structures of the resultant compounds were validated by physicochemical analytical methods, including X-ray diffraction. The computer-aided screening in the PASS prediction software discovered a high biological activity of the newly obtained compounds.

Recommanded Product: 67-51-6. About 3,5-Dimethyl-1H-pyrazole, If you have any questions, you can contact Glukhacheva, VS; Il’yasov, SG; Kazantsev, IV; Shestakova, EO; Il’yasov, DS; Eltsov, IV; Nefedov, AA; Gatilov, YV or concate me.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

Computed Properties of C11H12N2O. Recently I am researching about MAGNESIUM-DL-ASPARTATE; P-TOLUIC ACID; MIXING PROPERTIES; ACTIVITY-COEFFICIENT; NRTL-SAC; 313.15 K; PREDICTION; INGREDIENTS; PARAMETERS, Saw an article supported by the Payame Noor University. Published in ELSEVIER in AMSTERDAM ,Authors: Akbari, F; Didehban, K; Farhang, M. The CAS is 86-92-0. Through research, I have a further understanding and discovery of 3-Methyl-1-p-tolyl-5-pyrazolone

A new semi-theoretical equation is suggested for correlation of solid-liquid solubility data with temperature. The (solid + liquid) equilibrium for Terephthaldialdehyde, 4-Nitro-o-phennylenediamine, 2,4-dihydro- 5-methyl-2(4-methylphenyl)-3H-pyrazol-3-one (also named 1-(p-toly1)-3-methyl-5pyrazolone (PTMP)), 2-Amino-5-methylthiazole and 5-chloro-1-methyl-4-nitroimidazole in 18 solvents is correlated with semi-empirical models at temperatures T = 273.15 – 318.15 K under a pressure of 101.2 kPa. Moreover, a modified Apelblat model, lambda h model, Wilson model, NRTL model, new flexible equation as Akbari, Dideban and Farhang model (ADF) and for first time the modified Scatchard-Hildebrand equation were utilized to calculate the experiment values. The performance of both ADF and modified Scatchard-Hildebrand equation have been checked by calculating the solubility data with the AARD% of 1.3808% (for 775 data points) and 0.65% (for 100 data points), respectively. The Wilson model is applied to estimate the mixing Gibbs energy, mixing enthalpy, mixing entropy, activity coefficient (ln gamma(infinity)(1)) and reduced excess enthalpy (H-I(E,infinity)) at infinitesimal concentration were calculated.

Computed Properties of C11H12N2O. About 3-Methyl-1-p-tolyl-5-pyrazolone, If you have any questions, you can contact Akbari, F; Didehban, K; Farhang, M or concate me.

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics